These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 10462459)

  • 1. ACE inhibitors or AT(1) receptor blockers in heart failure?
    Rydén L
    Eur Heart J; 1999 Sep; 20(18):1287-9. PubMed ID: 10462459
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapeutic perspectives: association of ACE inhibitors and angiotensin receptor blockers].
    Costantino S; Millozzi F; Scarlata S
    Clin Ter; 2001; 152(2):77-8. PubMed ID: 11441526
    [No Abstract]   [Full Text] [Related]  

  • 3. [The role of ACE inhibitors and angiotensin receptor blockers in the treatment and prevention of chronic heart failure].
    Kárpáti P
    Orv Hetil; 2005 May; 146(18):827-31. PubMed ID: 15926627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Blockade of the renin-angiotensin system. ACE inhibitors, angiotensin II antagonists or both?].
    Karlsen FM; Kamper AL
    Ugeskr Laeger; 2003 Oct; 165(42):4006-9. PubMed ID: 14610833
    [No Abstract]   [Full Text] [Related]  

  • 5. The therapeutic role of RAS blockade in chronic heart failure.
    Werner CM; Böhm M
    Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):167-77. PubMed ID: 19124420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with ACE inhibitors and angiotensin-receptor blockers in heart failure.
    Scow DT; Smith EG; Shaughnessy AF
    Am Fam Physician; 2003 Nov; 68(9):1795-8. PubMed ID: 14620599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA; Movahed A
    Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease.
    Weber MA
    Rev Cardiovasc Med; 2002; 3(4):183-91. PubMed ID: 12556752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [ELITE II. AT1-blockers not better, but more tolerable than ACE-inhibitors].
    Berger D
    Internist (Berl); 2000 Jan; 41(1):A37. PubMed ID: 10712087
    [No Abstract]   [Full Text] [Related]  

  • 10. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure.
    Carson PE
    Am Heart J; 2000 Sep; 140(3):361-6. PubMed ID: 10966531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACE inhibitors vs. angiotensin II receptor blockers in acute myocardial infarction and heart failure.
    Gold JA; Rahko PS
    WMJ; 2004; 103(1):71-2. PubMed ID: 15101473
    [No Abstract]   [Full Text] [Related]  

  • 13. Are angiotensin-receptor blockers (ARBs) equivalent to or better than angiotensin-converting enzyme (ACE) inhibitors in the treatment of heart failure?
    Reigle J
    Crit Care Nurse; 2004 Dec; 24(6):67-9. PubMed ID: 15646090
    [No Abstract]   [Full Text] [Related]  

  • 14. Angiotensin II type 1 receptor blockade: a new development in cardiovascular pharmacology.
    Leary AC; MacDonald TM
    Int J Clin Pract; 1998 Oct; 52(7):475-81. PubMed ID: 10622089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effects of angiotensin II inhibition or blockade on the progression of chronic renal disease.
    Cantarovich F; Rangoonwala B
    Int J Clin Pract; 2003 Nov; 57(9):801-22. PubMed ID: 14686572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II receptor blockers in chronic heart failure--not as ELITE as expected!
    Farquharson CA; Struthers AD
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):21-2. PubMed ID: 11967790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II receptor blockers: current perspective.
    Agrawal V; Manohar G; Kasliwal RR
    J Assoc Physicians India; 2003 Jul; 51():706-13. PubMed ID: 14621043
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M; Solomon SD
    Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP
    Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.